Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2010 - 2026)

Rigel Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $24.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 46.62% year-over-year to $24.4 million in Q1 2026; TTM through Mar 2026 was $24.4 million, a 46.62% decrease from a year earlier, with the FY2025 full-year figure at $40.6 million, down 28.49% from the prior year.
• Cash & Equivalents slipped to $24.4 million in Q1 2026 per RIGL's latest filing, from $40.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $56.7 million in Q4 2024 and bottomed at $24.4 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $40.3 million (2023), against an average of $38.6 million.
• Across the five-year window, Cash & Equivalents sank 67.93% in 2022 and surged 79.45% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $24.5 million in 2022, then surged by 34.04% to $32.8 million in 2023, then surged by 73.08% to $56.7 million in 2024, then decreased by 28.49% to $40.6 million in 2025, then slumped by 39.84% to $24.4 million in 2026.
• Per Business Quant, the three latest RIGL Cash & Equivalents figures stand at $24.4 million (Q1 2026), $40.6 million (Q4 2025), and $48.5 million (Q3 2025).